Program
ocrelizumab
Also written as “Ocrelizumab”, “CYB704” and “OCR SC”.
Its studies are mostly in Multiple Sclerosis · Arthritis, Rheumatoid · Multiple Sclerosis, Chronic Progressive · Multiple Sclerosis, Relapsing-Remitting · Lupus Nephritis, led by 5 companies.
Drug pageOcrelizumab: every studyMany companies study it; this page follows only the 42 they lead. All 56 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Hoffmann-La Rocheits history only | 3810 open or running | phase 4since Jul 5, 2018 | Feb 12, 2004 | Dec 31, 2027phase 3 · NCT05269004 |
| Celltrionits history only | 11 open or running | phase 3since May 9, 2023 | May 9, 2023 | Feb 2027phase 3 · NCT05906992 |
| Cinnagenits history only | 10 open or running | phase 3since Jun 27, 2021 | Jun 27, 2021 | none ahead |
| R-Pharmits history only | 11 open or running | phase 1since Apr 13, 2026 | Apr 13, 2026 | none ahead |
| Sandozits history only | 11 open or running | phase 3since Feb 19, 2025 | Feb 19, 2025 | none ahead |
Also a collaborator on its studies: PPD Development, LP, Laboratory Corporation of America and Roche Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 26 studies since Feb 12, 2004.
- May 1, 2020Phase 4 study in Multiple SclerosisHoffmann-La Roche · NCT04377555 · 179 enrolled · United States, Kenya, Puerto Rico
- Sep 4, 20202 phase 3 studies in Multiple SclerosisHoffmann-La Roche · NCT04544436, NCT04548999
- Jun 27, 2021Cinnagen’s first study: phase 3 study in Multiple SclerosisNew to CinnagenCinnagen · NCT04966338 · 170 enrolled · Iran, Islamic Republic of
- Aug 6, 20212 phase 4 studies in Multiple SclerosisHoffmann-La Roche · NCT04998851, NCT04998812
- Nov 16, 2021Phase 3 study in Multiple Sclerosis, Relapsing-RemittingHoffmann-La Roche · NCT05123703 · 188 enrolled · United States, Argentina, Australia and more
- Jan 12, 2022Phase 4 study in Multiple SclerosisHoffmann-La Roche · NCT05208840 · Russian Federation
- Jan 27, 2022Phase 3 study in Multiple Sclerosis, Chronic ProgressiveHoffmann-La Roche · NCT05232825 · 236 enrolled · United States, Brazil, Czechia and more
- Feb 11, 2022Phase 3 study in Multiple SclerosisHoffmann-La Roche · NCT05269004 · 1,300 enrolled · United States, Argentina, Australia and more
- May 9, 2023Celltrion’s first study: phase 3 study in Multiple Sclerosis, Relapsing-RemittingNew to CelltrionCelltrion · NCT05906992 · 512 planned · Poland
- Nov 4, 2024Phase 3 study in Multiple SclerosisHoffmann-La Roche · NCT06675955 · 500 planned · Bulgaria, France, Germany and more
- Feb 19, 2025Sandoz’s first study: phase 3 study in Relapsing Multiple SclerosisNew to SandozSandoz · NCT06847724 · 183 enrolled · United States, Bosnia and Herzegovina, Bulgaria and more
- Mar 16, 2026Phase 4 study in Multiple Sclerosis, Chronic ProgressiveHoffmann-La Roche · NCT07483450 · 60 enrolled · China
- Apr 13, 2026R-Pharm’s first study: phase 1 study in Multiple SclerosisNew to R-PharmR-Pharm · NCT07597668 · 180 enrolled · Russia
- May 20, 2026Phase 4 study in Multiple SclerosisHoffmann-La Roche · NCT07609719 · 100 planned · United States, Puerto Rico
Ahead
- Nov 3, 2026Primary completion: phase 3 study in Relapsing Multiple SclerosisSandoz · NCT06847724
- Feb 2027Primary completion: phase 3 study in Multiple Sclerosis, Relapsing-RemittingCelltrion · NCT05906992
- Dec 31, 2027Primary completion: phase 4 study in Multiple Sclerosis, Chronic ProgressiveHoffmann-La Roche · NCT07483450
- Dec 31, 2027Primary completion: phase 3 study in Multiple SclerosisHoffmann-La Roche · NCT05269004
TargetBeta
“A Fc-modified, humanized monoclonal antibody directed against the B-cell CD20 cell surface antigen, with immunosuppressive activity”NCIt, by rule
“B-lymphocyte antigen CD20 binding agent”ChEMBL 37, by rule
Other programs on MS4A1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Rituximabrule | Hoffmann-La Roche | phase 4 | 175 |
| obinutuzumabrule | Hoffmann-La Roche | phase 4 | 42 |
| ublituximabrule | TG Therapeutics | phase 3 | 23 |
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| Anti-CD20 Monoclonal Antibody MIL62rule | beijing-mabworks-biotech-co-ltd | phase 3 | 10 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| TQB2825 | Sino Biopharmaceutical | phase 3 | 5 |
| zuberitamabrule | bioray-pharmaceutical-co-ltd | phase 3 | 3 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
| zamtocabtagene autoleucelrule | miltenyi-biomedicine-gmbh | phase 2 | 8 |
Studies
All 42 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07609719Multiple Sclerosis · United States, Puerto Rico | 4 | Recruiting | Hoffmann-La Roche | Feb 28, 2029 | 100 |
| NCT07597668Multiple Sclerosis · Russia | 1 | Active, not recruiting | R-Pharm | Jun 2, 2026 | 180 |
| NCT07483450Multiple Sclerosis, Chronic Progressive · China | 4 | Active, not recruiting | Hoffmann-La Roche | Dec 31, 2027 | 60 |
| NCT06847724Relapsing Multiple Sclerosis · United States, Bosnia and Herzegovina, Bulgaria and more | 3 | Active, not recruiting | Sandoz | Nov 3, 2026 | 183 |
| NCT06675955Multiple Sclerosis · Bulgaria, France, Germany and more | 3 | Recruiting | Hoffmann-La Roche | Dec 31, 2029 | 500 |
| NCT05906992Multiple Sclerosis, Relapsing-Remitting · Poland | 3 | Recruiting | Celltrion | Feb 2027 | 512 |
| NCT05269004Multiple Sclerosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Hoffmann-La Roche | Dec 31, 2027 | 1,300 |
| NCT05232825Multiple Sclerosis, Chronic Progressive · United States, Brazil, Czechia and more | 3 | Completed | Hoffmann-La Roche | Mar 10, 2023 | 236 |
| NCT05208840Multiple Sclerosis · Russian Federation | 4 | Withdrawn | Hoffmann-La Roche | Jan 31, 2025 | 0 |
| NCT05123703Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Australia and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 9, 2025 | 188 |
| NCT04998851Multiple Sclerosis · United States, Spain, United Kingdom | 4 | Completed | Hoffmann-La Roche | Mar 29, 2024 | 26 |
| NCT04998812Multiple Sclerosis · United States, France, Germany and more | 4 | Completed | Hoffmann-La Roche | Apr 8, 2024 | 70 |
| NCT04966338Multiple Sclerosis · Iran, Islamic Republic of | 3 | Completed | Cinnagen | Nov 9, 2020 | 170 |
| NCT04548999Multiple Sclerosis · United States, Argentina, Belgium and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jun 30, 2025 | 769 |
| NCT04544436Multiple Sclerosis · United States, Argentina, Australia and more | 3 | Active, not recruiting | Hoffmann-La Roche | Dec 19, 2024 | 864 |
| NCT04377555Multiple Sclerosis · United States, Kenya, Puerto Rico | 4 | Completed | Hoffmann-La Roche | Dec 15, 2022 | 179 |
| NCT04075266Multiple Sclerosis · United States, Italy, Poland | 2 | Active, not recruiting | Hoffmann-La Roche | Oct 5, 2023 | 23 |
| NCT04035005Multiple Sclerosis, Chronic Progressive · United States, Australia, Belgium and more | 3 | Active, not recruiting | Hoffmann-La Roche | Jan 15, 2025 | 1,013 |
| NCT03972306Multiple Sclerosis · United States | 1 | Completed | Hoffmann-La Roche | Jun 3, 2025 | 134 |
| NCT03606460Multiple Sclerosis · United States | 3 | Completed | Hoffmann-La Roche | May 31, 2019 | 141 |
| NCT03589105Multiple Sclerosis · France | 4 | Completed | Hoffmann-La Roche | Feb 15, 2021 | 423 |
| NCT03599245Multiple Sclerosis · Argentina, Belgium, Brazil and more | 3 | Completed | Hoffmann-La Roche | Jul 17, 2025 | 1,055 |
| NCT03523858Multiple Sclerosis, Chronic Progressive · United States, Bosnia and Herzegovina, Brazil and more | 3 | Active, not recruiting | Hoffmann-La Roche | Oct 22, 2026 | 927 |
| NCT03085810Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Australia and more | 3 | Terminated | Hoffmann-La Roche | Apr 27, 2023 | 1,225 |
| NCT02861014Multiple Sclerosis, Relapsing-Remitting · Australia, Belgium, Czechia and more | 3 | Completed | Hoffmann-La Roche | Oct 25, 2019 | 681 |
| NCT02723071Lymphoma, Non-Hodgkin · Australia, Canada, France and more | 2 | Completed | Hoffmann-La Roche | Jan 2008 | 48 |
| NCT02720120Arthritis, Rheumatoid · Australia, Belgium, Canada and more | 2 | Terminated | Hoffmann-La Roche | Feb 2013 | 175 |
| NCT02688985Multiple Sclerosis, Chronic Progressive · United States, Canada, Germany and more | 3 | Completed | Hoffmann-La Roche | Apr 11, 2023 | 131 |
| NCT02637856Multiple Sclerosis, Relapsing-Remitting · United States, Canada | 3 | Completed | Hoffmann-La Roche | May 3, 2019 | 608 |
| NCT01412333Relapsing Multiple Sclerosis · United States, Argentina, Belarus and more | 3 | Completed | Hoffmann-La Roche | May 12, 2015 | 835 |
| NCT01247324Relapsing Multiple Sclerosis · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Apr 2, 2015 | 821 |
| NCT01194570Multiple Sclerosis, Chronic Progressive · United States, Australia, Austria and more | 3 | Completed | Hoffmann-La Roche | Jul 23, 2015 | 735 |
| NCT00808210Arthritis, Rheumatoid · United States | 2 | Terminated | Hoffmann-La Roche | Nov 14, 2012 | 28 |
| NCT00779220Arthritis, Rheumatoid · Japan | 2 | Terminated | Hoffmann-La Roche | Feb 2010 | 152 |
| NCT00676715Multiple Sclerosis, Relapsing-Remitting · United States, Belgium, Bulgaria and more | 2 | Completed | Hoffmann-La Roche | Mar 9, 2012 | 220 |
| NCT00673920Arthritis, Rheumatoid | 3 | Terminated | Hoffmann-La Roche | Oct 26, 2009 | 314 |
| NCT00626197Lupus Nephritis | 3 | Terminated | Hoffmann-La Roche | Oct 19, 2009 | 381 |
| NCT00539838Lupus Erythematosus, Systemic | 3 | Terminated | Hoffmann-La Roche | Jul 12, 2011 | 33 |
| NCT00485589Arthritis, Rheumatoid | 3 | Terminated | Hoffmann-La Roche | Jan 29, 2010 | 613 |
| NCT00476996Arthritis, Rheumatoid · United States, Argentina, Australia and more | 3 | Terminated | Hoffmann-La Roche | Jan 21, 2010 | 836 |
| NCT00406419Arthritis, Rheumatoid · United States | 3 | Terminated | Hoffmann-La Roche | Oct 6, 2009 | 1,015 |
| NCT00077870Arthritis, Rheumatoid | 2 | Completed | Hoffmann-La Roche | 237 |
How it is read
Names in the registry
- “Ocrelizumab”, 36 entries
- “ocrelizumab”, 2 entries
- “CYB704”, 1 entry
- “OCR SC”, 1 entry
- “Ocrelizumab SC”, 1 entry
Conditions, from the studies’ own filings
- Multiple Sclerosis, 18 studies
- Arthritis, Rheumatoid, 8 studies
- Multiple Sclerosis, Chronic Progressive, 7 studies
- Multiple Sclerosis, Relapsing-Remitting, 6 studies
- Lupus Nephritis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.